The CANTOS trial (Canakinumab Anti‐inflammatory Thrombosis Outcome Study), a multinational double‐blind phase III study, was also designed to target inflammation in patients with established atherosclerotic disease who had prior myocardial infarction and high residual systemic inflammatory state (measured by high‐sensitivity CRP levels >2 mg/L)—comparable to the chronic inflammatory state after stroke (Ridker et al, 2017). Here, CRP is linked to Stroke.